Samsung Biologics recently gave up developing SAIT101, a biosimilar of follicular lymphoma treatment Rituxan, which it had promoted as its first product since entering the bio business. According to the Samsung Biologics’ quarterly report released this week, the company and AstraZeneca, decided in September to suspend research and development activities by their joint venture, Archigen Biotech, and liquidate the latter. The two companies had set up the tie-up firm to focus on developing only the anticancer drug. Samsung Biologics has invested about $126 million into Archigen Biotech since its founding.
Learn More